Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock. D. Boral Capital’s target price indicates a potential upside of 124.22% from the company’s current price.

Several other equities analysts also recently commented on HOTH. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a research note on Monday, November 4th. Benchmark reissued a “speculative buy” rating and set a $3.00 target price on shares of Hoth Therapeutics in a research note on Friday, October 11th.

Hoth Therapeutics Trading Up 172.1 %

Shares of HOTH stock traded up $1.41 during trading on Tuesday, reaching $2.23. 335,950,001 shares of the company’s stock traded hands, compared to its average volume of 82,185,336. Hoth Therapeutics has a 1 year low of $0.58 and a 1 year high of $3.80. The firm’s 50-day moving average is $0.83 and its 200 day moving average is $0.84. The company has a market capitalization of $15.40 million, a P/E ratio of -1.69 and a beta of 0.75.

Hoth Therapeutics (NASDAQ:HOTH) last announced its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). As a group, sell-side analysts predict that Hoth Therapeutics will post -1.18 earnings per share for the current fiscal year.

Institutional Trading of Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics at the end of the most recent reporting period. 7.08% of the stock is owned by institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.